Stuart and Sorenson found that venture funding and a cluster of comparable enterprises in an area affect biotech IPOs. They observed that biotech businesses with a high potential of going public are more likely to be invested in by venture capital firms in locations with a high concentration of venture capital. They also showed that places with a cluster of comparable biotech businesses had a greater possibility of biotech firms going public due to improved cooperation and information exchange, which may boost individual company performance. 